Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy

09/15/2021 | 07:27am EDT

Sept 15 (Reuters) - Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.

The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.

Lilly said its deal with the U.S government is expected to generate approximately $330 million in revenue in the second half of 2021, with about 200,000 doses expected to be shipped in the third quarter this year and the remaining in fourth.

"The recent increase in COVID-19 cases has caused a substantial rise in the utilization of monoclonal antibody drugs, particularly in areas of the country with low vaccination rates," Lilly's chief scientific and medical officer Daniel Skovronsky said.

The drugmaker will supply additional doses of etesevimab to be paired with doses of its other COVID-19 antibody therapy, bamlanivimab, previously purchased by the U.S. government.

Bamlanivimab and etesevimab are authorized for use in people 12 years and above with mild-to-moderate infection and at high risk for progression to severe COVID-19. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


© Reuters 2021
All news about REGENERON PHARMACEUTICALS
04:50aSANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
04:24aREGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
01:50aSANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/20SANOFI : Regeneron Win Expanded US FDA Nod for Asthma Drug Dupixent
MT
10/20REGENERON PHARMACEUTICALS : Sanofi Say FDA Has Expanded Approval of Dupixent to Include Ch..
MT
10/20REGENERON PHARMACEUTICALS : FDA Expands Approval of Dupixent® (dupilumab) to Include Child..
PR
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14Health Care Stocks Climb Pre-Bell Thursday
MT
10/14REGENERON PHARMACEUTICALS : US FDA Accepts Regeneron's Regen-Cov For Priority Review for C..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net Debt 2021 - - -
P/E ratio 2021 8,65x
Yield 2021 -
Capitalization 59 507 M 59 507 M -
Capi. / Sales 2021 4,13x
Capi. / Sales 2022 4,88x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 572,36 $
Average target price 681,64 $
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS18.47%59 196
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE241.44%69 162
WUXI APPTEC CO., LTD.24.51%65 142
VERTEX PHARMACEUTICALS-22.35%48 536
BEIGENE, LTD.46.63%35 024